German chemical and lifesciences firm Bayer has reported positive results from the Phase II CHRONOS-1 clinical trial of copanlisib for the treatment of indolent non-Hodgkin's lymphoma (iNHL) patients.

Copanlisib is an investigational intravenous pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor, which has predominant inhibitory activity against PI3K-α and PI3K-δ isoforms.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company noted that the primary endpoint of a pre-specified objective response rate (ORR) was met in the trial.

The open-label, single-arm Phase II trial investigated the efficacy and safety of the product in 142 patients with relapsed or refractory iNHL, including follicular lymphoma (FL) who received a minimum of two prior therapies.

Bayer oncology strategic business unit executive vice-president and head Robert LaCaze said: "NHL is the tenth most common cancer worldwide and one of the most common cancers in the US.

"NHL is the tenth most common cancer worldwide and one of the most common cancers in the US."

"Despite treatment advances, most indolent NHL patients relapse after, or are refractory to, current therapies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"The positive results from CHRONOS-1 are an important milestone and reflect the potential clinical utility of copanlisib in addressing the unmet medical need in patients with malignant lymphoma."

While the trial's primary endpoint was objective tumour response rate, the secondary endpoints included duration of response, overall survival, progression-free survival, quality of life and safety.

The US Food and Drug Administration (FDA) has granted fast-track designation for copanlisib in relapsed or refractory FL, as well as orphan drug designation (ODD) to treat FL.

The product has also obtained ODD for the treatment of patients with splenic, nodal, and extranodal subtypes of marginal zone lymphoma (MZL).

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact